AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 11/04/22

Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q3 Non-GAAP EPS of $0.14 misses by $0.04 . Revenue of $545.56M (+3.2% Y/Y) misses by $16.61M . Reaffirms FY2022 Guidance : Reaffirms Net revenue to $2.15B-$2.25B vs. consensus of $2.20B; Adj EPS from pr...

‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Full Year Outlook ‒ ...

Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q3 earnings results on Friday, November 4th, before market open. The consensus EPS Estimate is $0.18 (-14.3% Y/Y) and the consensus Revenue Estimate is $562.17M (+6.3% Y/Y). Over the last 2 years, AMRX ha...

Amneal Pharmaceuticals ( NYSE: AMRX ) on Wednesday said it had received an abbreviated new drug application approval from the U.S. FDA for its leuprolide acetate injection to treat prostate cancer. AMRX expects to launch eight new injectables in 2022, the company said in a...

Company expects to launch 8 new injectables in 2022 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administrat...

Summary Shares of generic and specialty drug maker Amneal Pharmaceuticals, Inc. (AMPX) are down approximately 90% over the past four years as its attempt to transform itself has produced middling results. As the company pivots away from oral pills in favor of injectables, complex ...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern ...

First of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of ALYMSYS ® (bevacizumab-maly), a biosimilar referenci...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022. Mr. Pesquin joins the Company from Sanof...

Amneal Pharmaceuticals ( NYSE: AMRX ) has submitted a New Drug Application to the US FDA for IPX203 , carbidopa/levodopa (CD/LD) extended-release capsules for Parkinson’s disease. The application is based on phase 3 data that showed more "good on" time compared ...